Menadiol sodium sulfate
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Menadiol sodium sulfate
- Molecular weight
- 378.29
- Structure (SMILES)
- Cc1cc(OS(=O)(=O)[O-])c2ccccc2c1OS(=O)(=O)[O-].[Na+].[Na+]
- 1 4 naphthalenediol 2 methyl 1 4 bis hydrogen sulfate sodium salt 1 2
- 1 4 naphthalenediol 2 methyl bis h sulfate disodium salt
- 1,4-NAPHTHALENEDIOL, 2-METHYL-, 1,4-BIS(HYDROGEN SULFATE), SODIUM SALT (1:2)
- 1,4-NAPHTHALENEDIOL, 2-METHYL-, BIS(H SULFATE), DISODIUM SALT
- 2 methyl 1 4 naphthalenediol bis hydrogen sulfate disodium salt
- 2-METHYL-1,4-NAPHTHALENEDIOL BIS(HYDROGEN SULFATE) DISODIUM SALT
- disodium menadiol disulfate
- Disodium menadiol disulfate
- menadiol dipotassium disulfate
- Menadiol dipotassium disulfate
- menadiol disodium disulfate
- Menadiol disodium disulfate
- menadiol sodium sulfate
- Menadiol sodium sulfate
- menadiol sodium sulfate [INN]
- Menadiol sodium sulfate [WHO-DD]
- menadiol sodium sulfate inn
- menadiol sodium sulfate who dd
- menadiol sodium sulphate
- Menadiol sodium sulphate
- sulfate sodique de menadiol
- Sulfate sodique de menadiol
- sulfato de menadiol y sodio
- Sulfato de menadiol y sodio
- vikastab
And 1 more, listed on the interactive page.
- CAS registry numbers
- 1612-30-2
- ChEMBL ID
- CHEMBL2106883
- InChIKey
- VIXBZWJMHHVLBT-UHFFFAOYSA-L
- PubChem compound IDs
- 71102
- FDA ingredient codes (UNII)
- LCF9984C2K
- First in class
- No
- Orphan designation
- No
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 2
- Polar surface area
- 127.2
- Calculated partition coefficient (ALogP)
- 1.51
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 23
- Molecular formula
- C11H8Na2O8S2
- Monoisotopic mass
- 377.94559812
- Natural product
- No
Related records
Trials (12)
- A Phase I/IIa AERAS-456 in HIV-Negative Adults With & Without Latent Tuberculosis Infection (C-035-456)
- A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age
- Bioequivalence Study of Telmisartan Between T80/A5/H12.5 mg FDC Tablet and T80/A5 mg Tab and H12.5 mg Tab Concomitant Use
- Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg (T80/A5/H12.5 mg) Fixed-dose Combination (FDC) Tablet and T80/H12.5 mg Tab and A5 mg (Encap A2.5 mg Tab x2) Concomitant Use
- Clazosentan in Aneurysmal Subarachnoid Hemorrhage
- Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection
- Genomic Response Analysis of Heart Failure Therapy in African Americans
- Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)
- PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer
- Safety And Efficacy Of Dexmedetomidine Sedation In Intubated Mechanically Ventilated Infants With Respiratory Failure
- Trastuzumab Based Therapy in HER2 Positive AGC
- Treatment of Tuberculosis Multidrug Resistance Treatment of Tuberculosis Multidrug Resistance